In contrast to other driver oncogenes in lung cancer, such as EGFR and ALK, molecularly targeted drugs to KRAS have not yet been developed and therapeutic targeting of KRAS-mutated lung adenocarcinoma remains a huge challenge. This evidence concerns the gene EGFR and lung adenocarcinoma.